By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Boston Therapeutics, Inc. 

1750 Elm Street, Suite 103

Manchester  New Hampshire  03104  U.S.A.
Phone: 603-935-9799 Fax: 603-685-4784



Company News
Boston Therapeutics, Inc. Announces FDA Acceptance Of IND To Initiate A Clinical Trial Of BTI-320 To Treat Type ll Diabetes And Weight Loss 12/11/2014 8:14:14 AM
Boston Therapeutics, Inc. and Advance Pharmaceutical Expand Agreement To Market Sugardown® In 12 Additional Countries In Asia 11/24/2014 9:48:37 AM
Boston Therapeutics, Inc. Initiates Clinical Study At Sydney University To Evaluate sSugardown® With Sugary Beverage Consumption 11/19/2014 12:57:52 PM
Boston Therapeutics, Inc. Reports Third Quarter Results And Provides Corporate Update 11/10/2014 10:50:05 AM
Boston Therapeutics, Inc. Announces The North America Branding Of Sugardown®: A New Natural Product That Helps Maintain Healthy Blood Sugar Levels 11/4/2014 1:08:22 PM
Boston Therapeutics, Inc. Reports Topline U.S.-Based Phase 2b Study Results Of BTI-320 In Patients With Type 2 Diabetes 10/9/2014 8:01:18 AM
Boston Therapeutics, Inc. Appoints David S.H. Bell, MB, FACP, FACE To Its Medical Advisory Board 10/8/2014 9:36:16 AM
Boston Therapeutics, Inc. Files Patent Application For Novel Therapeutic Uses Of BTI-320 10/7/2014 10:22:15 AM
Boston Therapeutics, Inc. Appoints Jan Brinkman, M.D., Ph.D. And Alan M. Hoberman, Ph.D. To Board Of Directors 10/2/2014 10:53:56 AM
Benchworks Collaborates With Boston Therapeutics, Inc. To Market Sugardown® 9/29/2014 12:28:26 PM